![]() ![]() Sign up for free Altmetric alerts about this article - Sign up for free Altmetric alerts about this articleĬorrespondence to - Vladimir N. Taking into consideration the optimistic conclusions obtained in our work, based on large clinical material, it is advisable to conduct prospective randomized studies with an assessment of survival rates in patients with PCa of various prognosis groups.” The Anisimov Research Team concluded in their Oncotarget Research Paper that “the results of our study are in agreement with the data on favorable antitumor effect melatonin treatment of patients with advanced cancer of various localization, mainly in the breast, uterus, colon, etc. The aim of the study was to improve the effectiveness of treatment of patients with prostate cancer by long-term use of melatonin drugs after a course of combined hormone-radiation treatment. Thus, the assessment of long-term results of wide clinical use of melatonin in the combined treatment of patients with prostate cancer of various risk groups is an urgent and relevant task. The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown. Some possible points of inhibition of tumor growth by melatonin included activation of T helper type 1 increased production of several cytokines inhibition of angiogenesis reduced expression of the VEGF receptors activation of apoptosis in tumor cells and a decrease in telomerase activity. The system allows us to take into account the specifics of the data mining task be- ing solved and set the priority of assessing the ML model quality based on. Melatonin is most widely used in clinical practice to treat hormone-dependent tumors, and primarily in the combined treatment of breast cancer. Petrov National Medical Research Center of Oncology said, "Melatonin is the main hormone of the pineal gland." Interview regarding his article published in Oncotarget Volume 11, Issue 41 titled Melatonin increases overall survival of prostate cancer patients with. The multicomponent antitumor effect of melatonin is fully realized and clearly demonstrated in treatment of PCa patients with poor prognosis with a set of unfavorable factors of the tumor progression.ĭr. In a multivariate analysis, melatonin administration proved to be an independent prognostic factor and reduced the risk of death of PCa patients by more than twice. In the poor prognosis group, the median overall survival in patients taking the drug was 153.5 months versus 64.0 months in patients not using it. The overall survival rate of PCa patients with favorable and intermediate prognoses treated or not treated with melatonin was not statistically significantly different. Comprehensive statistical methods were used to analyze the overall survival rate of PCa patients treated with melatonin in various prognosis groups. Oncotarget recently published "Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment" which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019. Petrov National Medical Research Center of Oncology ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |